Mamas, MA ORCID: 0000-0001-9241-8890, Sperrin, M, Watson, MC, Coutts, A, Wilde, K, Burton, C, Kadam, UT, Kwok, CS, Clarke, AB, Murchie, P, Buchan, I, Hannaford, PC and Myint, PK (2017) Do patients have a worse outcome with heart failure than cancer? A primary care based cohort study with 10-year follow-up in Scotland. European Journal of Heart Failure, 19 (9). pp. 1095-1104. ISSN 1879-0844

[img]
Preview
Text
mamas_heart_fail_feb_2017.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (91kB) | Preview
[img] Text
Table 3 Final.doc - Supplemental Material
Available under License Creative Commons Attribution Non-commercial.

Download (41kB)
[img] Text
Table 2 MS Final.doc - Supplemental Material
Available under License Creative Commons Attribution Non-commercial.

Download (99kB)
[img] Text
Table 1 MS Final.doc - Supplemental Material
Available under License Creative Commons Attribution Non-commercial.

Download (100kB)
[img]
Preview
Image
Fig 2 HQ final.tif - Supplemental Material
Available under License Creative Commons Attribution Non-commercial.

Download (5MB) | Preview
[img]
Preview
Image
fig3HQ.tif - Supplemental Material
Available under License Creative Commons Attribution Non-commercial.

Download (5MB) | Preview
[img]
Preview
Image
Figure 1A.jpeg - Supplemental Material
Available under License Creative Commons Attribution Non-commercial.

Download (95kB) | Preview
[img]
Preview
Image
Figure 1B.jpeg - Supplemental Material
Available under License Creative Commons Attribution Non-commercial.

Download (97kB) | Preview

Abstract

Aims
This study was designed to evaluate whether survival rates in patients with heart failure (HF) are better than those in patients with diagnoses of the four most common cancers in men and women, respectively, in a contemporary primary care cohort in the community in Scotland.

Methods and results
Data were obtained from the Primary Care Clinical Informatics Unit from a database of 1.75 million people registered with 393 general practices in Scotland. Sex‐specific survival modelling was undertaken using Cox proportional hazards models, adjusted for potential confounders. A total of 56 658 subjects were eligible for inclusion in the study. These represented a total of 147 938 person‐years of follow‐up (median follow‐up: 2.04 years). In men, HF (reference group; 5‐year survival: 55.8%) had worse mortality outcomes than prostate cancer [hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.57–0.65; 5‐year survival: 68.3%], and bladder cancer (HR 0.88, 95% CI 0.81–0.96; 5‐year survival: 57.3%), but better outcomes than lung cancer (HR 3.86, 95% CI 3.65–4.07; 5‐year survival: 8.4%) and colorectal cancer (HR 1.23, 95% CI 1.16–1.31; 5‐year survival: 48.9%). In women, HF (reference group; 5‐year survival: 49.5%) had worse mortality outcomes than breast cancer (HR 0.55, 95% CI 0.51–0.59; 5‐year survival 77.7%), but better outcomes than colorectal cancer (HR 1.21, 95% CI 1.13–1.29; 5‐year survival 51.5%), lung cancer (HR 3.82, 95% CI 3.60–4.05; 5‐year survival 10.4%), and ovarian cancer (HR 1.98, 95% CI 1.80–2.17; 5‐year survival 38.2%).

Conclusions
Despite advances in management, HF remains as ‘malignant’ as some of the common cancers in both men and women.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Wiley at http://dx.doi.org/10.1002/ejhf.822 Please refer to any applicable terms of use of the publisher.
Subjects: R Medicine > RC Internal medicine > RC666 Diseases of the circulatory (Cardiovascular) system
Divisions: Faculty of Medicine and Health Sciences > Institute for Science and Technology in Medicine
Depositing User: Symplectic
Date Deposited: 28 Feb 2017 13:41
Last Modified: 22 Jun 2018 14:46
URI: http://eprints.keele.ac.uk/id/eprint/2954

Actions (login required)

View Item View Item